[
  {
    "ts": "2026-02-01T10:05:53+00:00",
    "headline": "Boston Scientific Reshapes Portfolio With Nalu And Penumbra Neuro Deals",
    "summary": "Boston Scientific (NYSE:BSX) has completed the acquisition of Nalu Medical, expanding its presence in chronic pain treatment. The company has announced a pending US$14.5b deal for Penumbra, which would significantly increase its scale in neurovascular devices. These transactions represent a major reshaping of BSX’s portfolio in neuromodulation and neurovascular care. Boston Scientific is a large medical device company with products across cardiology, peripheral interventions, urology and...",
    "url": "https://finance.yahoo.com/news/boston-scientific-reshapes-portfolio-nalu-100553675.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "4833d27c-511d-328b-bfb6-87874a481c7b",
      "content": {
        "id": "4833d27c-511d-328b-bfb6-87874a481c7b",
        "contentType": "STORY",
        "title": "Boston Scientific Reshapes Portfolio With Nalu And Penumbra Neuro Deals",
        "description": "",
        "summary": "Boston Scientific (NYSE:BSX) has completed the acquisition of Nalu Medical, expanding its presence in chronic pain treatment. The company has announced a pending US$14.5b deal for Penumbra, which would significantly increase its scale in neurovascular devices. These transactions represent a major reshaping of BSX’s portfolio in neuromodulation and neurovascular care. Boston Scientific is a large medical device company with products across cardiology, peripheral interventions, urology and...",
        "pubDate": "2026-02-01T10:05:53Z",
        "displayTime": "2026-02-01T10:05:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sFax.1EIpS7VVYvaDN0jRw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OB69YGFZw788CGHTsahrkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientific-reshapes-portfolio-nalu-100553675.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientific-reshapes-portfolio-nalu-100553675.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            },
            {
              "symbol": "PEN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]